WO1987002662A3 - Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques - Google Patents

Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques Download PDF

Info

Publication number
WO1987002662A3
WO1987002662A3 PCT/EP1986/000598 EP8600598W WO8702662A3 WO 1987002662 A3 WO1987002662 A3 WO 1987002662A3 EP 8600598 W EP8600598 W EP 8600598W WO 8702662 A3 WO8702662 A3 WO 8702662A3
Authority
WO
WIPO (PCT)
Prior art keywords
3alkyl
hydrogen
group
formula
pharmaceuticals
Prior art date
Application number
PCT/EP1986/000598
Other languages
English (en)
Other versions
WO1987002662A2 (fr
Inventor
James Richard Wareing
Robert Edson Damon
Original Assignee
Sandoz Ag
Sandoz Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag, Sandoz Pharmaceuticals Corp filed Critical Sandoz Ag
Priority to KR1019870700553A priority Critical patent/KR900001212B1/ko
Priority to HU865313A priority patent/HUT48208A/hu
Publication of WO1987002662A2 publication Critical patent/WO1987002662A2/fr
Priority to FI872299A priority patent/FI872299A0/fi
Priority to DK321887A priority patent/DK321887D0/da
Publication of WO1987002662A3 publication Critical patent/WO1987002662A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule (I) dans laquelle Ra est un groupe -X-Z, Rb est R2, Rc est R3, Rd est R4 et Y est un groupe (III) ou Ra est R1, Rb est un groupe -X-Z, Rc est R2, Rd est R3 et Y est O, S ou un groupe (IV); R1, R2, R3 et R4 sont chacun indépendamment C1-6alkyle ne contenant pas d'atome de carbone asymétrique, C3-7cycloalkyle ou un anneau (V) ou, dans le cas R3 et R4, également hydrogène, ou, lorsque Y est O ou S, R3 et représenté par (VI) où R17 est hydrogène ou C1-3alkyle et R18 et R19 sont indépendamment hydrogène, C1-3alkyle ou phényle; chaque R5 est indépendamment hydrogène, C1-3alkyle, n-butyle, i-butyle, t-butyle, C1-3alkoxy, n-butoxy, i-butoxy, trifluorométhyle, fluoro, chloro, bromo, phényle, phénoxy ou benzyloxy; chaque R6 est indépendamment hydrogène, C1-3alkyle, C1-3alkoxy, trifluorométhyle, fluoro, chloro, bromo, phénoxy ou benzyloxy, et chaque R7 est indépendamment hydrogène, C1-2alkyle, C1-2alkoxy, fluoro ou chloro, à condition que chaque anneau A ne puisse présenter qu'un élément parmi trifluorométhyle, phénoxy ou benzyloxy, X est (CH2)m ou (CH2)qCH=CH-(CH2)q, m vaut 0, 1, 2 ou 3 et les deux q valent 0 ou l'un d'entre eux vaut 0 et l'autre vaut 1, Z présente la formule (II) où R9 est hydrogène ou C1-3alkyle. Ces composés se présentent sous la forme d'un acide libre, ou sous la forme d'un ester ou d'un delta-lactone de celui-ci ou sous une forme de sel, selon les besoins, et sont indiqués pour être utilisés comme produits pharmaceutiques notamment en tant qu'agents hypolipoprotéinémiques et anti-artériosclérotiques.
PCT/EP1986/000598 1985-10-25 1986-10-21 Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques WO1987002662A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019870700553A KR900001212B1 (ko) 1985-10-25 1986-10-21 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
HU865313A HUT48208A (en) 1985-10-25 1986-10-21 Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds
FI872299A FI872299A0 (fi) 1985-10-25 1987-05-25 Heterocykliska analoger av mevalonolaktoner och deras derivat, foerfaranden foer deras framstaellning och deras anvaendning som farmaceutiska medel.
DK321887A DK321887D0 (da) 1985-10-25 1987-06-24 Mevalonolactonanaloge

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79119885A 1985-10-25 1985-10-25
US791,198 1985-10-25
US81666486A 1986-01-07 1986-01-07
US816,664 1986-01-07

Publications (2)

Publication Number Publication Date
WO1987002662A2 WO1987002662A2 (fr) 1987-05-07
WO1987002662A3 true WO1987002662A3 (fr) 1987-12-17

Family

ID=27121116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1986/000598 WO1987002662A2 (fr) 1985-10-25 1986-10-21 Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques

Country Status (12)

Country Link
EP (1) EP0221025A1 (fr)
KR (1) KR900001212B1 (fr)
AU (1) AU598775B2 (fr)
CA (1) CA1278794C (fr)
DK (1) DK321887D0 (fr)
FI (1) FI872299A0 (fr)
HU (1) HUT48208A (fr)
IL (1) IL80403A (fr)
NZ (1) NZ218045A (fr)
PL (1) PL154130B1 (fr)
PT (1) PT83610B (fr)
WO (1) WO1987002662A2 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
NO881411L (no) * 1987-04-14 1988-10-17 Bayer Ag Substituerte pyrroler.
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3817808A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890988L (no) * 1988-03-24 1989-09-25 Bayer Ag Disubstituerte pyrroler.
EP0339342A1 (fr) * 1988-04-23 1989-11-02 Bayer Ag N-aminopyrrols N-substitués
EP0352575A3 (fr) * 1988-07-28 1991-08-21 Bayer Ag Pyrroles annelés substitués
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
ES2019163A6 (es) * 1988-10-03 1991-06-01 Glaxo Group Ltd Procedimiento para preparar derivados de imidazol.
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EP0422895A1 (fr) * 1989-10-10 1991-04-17 Glaxo Group Limited Composés chimiques
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
WO1992019239A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'etats cellulaires aberrants a l'aide de biomodulateurs
WO1992019240A1 (fr) * 1991-05-01 1992-11-12 University Of New Mexico Traitement d'aberrations cellulaires avec des biomodulateurs
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
ES2213601T3 (es) 1999-09-14 2004-09-01 MERCK FROSST CANADA & CO. Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimiento de tratamiento.
EP1216241B1 (fr) 1999-09-14 2005-12-07 Merck Frosst Canada & Co. Acides carboxyliques et acylsulfonamides, compositions contenant de tels composes et methodes de traitement
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1572892A4 (fr) 2001-10-18 2007-08-22 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (fr) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
AU2003241477A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2004037181A2 (fr) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7250444B2 (en) 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
SI1725234T2 (sl) 2004-03-05 2016-05-31 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih učinkov
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques constituant des modulateurs des recepteurs cannabinoides
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
WO2007053819A2 (fr) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Inhibiteurs à base d'amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2089355A2 (fr) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (ja) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
WO2009038974A1 (fr) 2007-09-20 2009-03-26 Irm Llc Composés et compositions en tant que modulateurs de l'activité de gpr119
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20100256153A1 (en) 2009-03-27 2010-10-07 Bristol-Myers Squibb Company Methods for preventing or reducing risk of mortality
WO2011014520A2 (fr) 2009-07-29 2011-02-03 Irm Llc Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
EP2486033A1 (fr) 2009-10-09 2012-08-15 Irm Llc Composes et compositions comme modulateurs de l'activite de gpr119
AU2010319438B2 (en) 2009-11-13 2015-05-21 Astrazeneca Uk Limited Reduced mass metformin formulations
US8535715B2 (en) 2009-11-13 2013-09-17 Bristol-Myers Squibb Company Bilayer tablet formulations
US8871264B2 (en) 2009-11-13 2014-10-28 Astrazeneca Ab Immediate release tablet formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
JP6042330B2 (ja) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (fr) 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
US9200025B2 (en) 2012-11-20 2015-12-01 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
WO2015027021A1 (fr) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
EP3191098A4 (fr) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
EP3288584A2 (fr) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
WO2020068661A1 (fr) 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Formes cristallines de n-(1 -((2-(diméthylamino)éthyl)amino)-2-m éthyl-1 -oopropan-2-yl)-4-(4-(2-méthyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(méthylthio)tétrahydro-2h-pyran-2-yl)benzyl) phényl)butanamide et procédés de synthèse associés

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168527A (en) * 1962-06-14 1965-02-02 Parke Davis & Co 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds
DE1695941A1 (de) * 1966-04-25 1971-05-13 Upjohn Co Verfahren zur Herstellung von 5-gliedrigen N-Heterocyclen,die im Ring ungesaettigt sind
FR2164857A1 (fr) * 1971-12-23 1973-08-03 Continental Pharma
US4035394A (en) * 1976-02-24 1977-07-12 Morton-Norwich Products, Inc. 5-Phenyl-2-furanyl-oxo or-hydroxy alkanoic acids and ethyl esters as gastric acid antisecretory agents
EP0117228A1 (fr) * 1983-01-24 1984-08-29 Sandoz Ag Analogues de mévalonolactone et leur dérivés, leur procédé de production, compositions pharmaceutiques les contenant ainsi que leur utilisation comme médicaments
EP0125415A1 (fr) * 1983-03-16 1984-11-21 BASF Aktiengesellschaft Procédé de production de pyrroles
AT377255B (de) * 1982-06-22 1985-02-25 Richter Gedeon Vegyeszet Verfahren zur herstellung von 1-alkyl- bzw. 1,4-dialkyl-1h-pyrrol-2-essigsaeure-alkylestern
EP0155524A1 (fr) * 1984-03-01 1985-09-25 A. Nattermann & Cie. GmbH Composé omega-aryl-alkylthianyliques, leur procédé de préparation et produits pharmaceutiques les contenant
WO1986000307A2 (fr) * 1984-06-22 1986-01-16 Sandoz Ag Analogues pyrazole de la mevalonolactone et leurs derives, leurs procedes de preparation et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168532A (en) * 1963-06-12 1965-02-02 Parke Davis & Co 1, 5-diarylpyrrole-2-propionic acid compounds
WO1984002131A1 (fr) * 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
DE3581638D1 (de) * 1984-12-04 1991-03-07 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168527A (en) * 1962-06-14 1965-02-02 Parke Davis & Co 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds
DE1695941A1 (de) * 1966-04-25 1971-05-13 Upjohn Co Verfahren zur Herstellung von 5-gliedrigen N-Heterocyclen,die im Ring ungesaettigt sind
FR2164857A1 (fr) * 1971-12-23 1973-08-03 Continental Pharma
US4035394A (en) * 1976-02-24 1977-07-12 Morton-Norwich Products, Inc. 5-Phenyl-2-furanyl-oxo or-hydroxy alkanoic acids and ethyl esters as gastric acid antisecretory agents
AT377255B (de) * 1982-06-22 1985-02-25 Richter Gedeon Vegyeszet Verfahren zur herstellung von 1-alkyl- bzw. 1,4-dialkyl-1h-pyrrol-2-essigsaeure-alkylestern
EP0117228A1 (fr) * 1983-01-24 1984-08-29 Sandoz Ag Analogues de mévalonolactone et leur dérivés, leur procédé de production, compositions pharmaceutiques les contenant ainsi que leur utilisation comme médicaments
EP0125415A1 (fr) * 1983-03-16 1984-11-21 BASF Aktiengesellschaft Procédé de production de pyrroles
EP0155524A1 (fr) * 1984-03-01 1985-09-25 A. Nattermann & Cie. GmbH Composé omega-aryl-alkylthianyliques, leur procédé de préparation et produits pharmaceutiques les contenant
WO1986000307A2 (fr) * 1984-06-22 1986-01-16 Sandoz Ag Analogues pyrazole de la mevalonolactone et leurs derives, leurs procedes de preparation et leur utilisation

Also Published As

Publication number Publication date
EP0221025A1 (fr) 1987-05-06
NZ218045A (en) 1990-03-27
FI872299A (fi) 1987-05-25
DK321887A (da) 1987-06-24
PL262032A1 (en) 1988-07-21
KR900001212B1 (ko) 1990-02-28
AU6599486A (en) 1987-05-19
PT83610A (en) 1986-11-01
PL154130B1 (en) 1991-07-31
FI872299A0 (fi) 1987-05-25
AU598775B2 (en) 1990-07-05
IL80403A (en) 1990-09-17
HUT48208A (en) 1989-05-29
IL80403A0 (en) 1987-01-30
DK321887D0 (da) 1987-06-24
CA1278794C (fr) 1991-01-08
WO1987002662A2 (fr) 1987-05-07
KR870700602A (ko) 1987-12-30
PT83610B (pt) 1989-05-31

Similar Documents

Publication Publication Date Title
WO1987002662A3 (fr) Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques
ATE62906T1 (de) Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
ES8800250A1 (es) Procedimiento para preparar acidos propano-fosfonosos susti-tuidos
ATE60571T1 (de) Inden-analoga von mevalonolakton und ihre derivate.
DE3574137D1 (en) Pyridazinones, their preparation and use, medicaments containing pyridazinones
DK165244C (da) Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler
ES467565A1 (es) Procedimiento para la preparacion de nuevas 4-acilamino-fe- nil-etanol-aminas.
EP0154234A3 (fr) Amides de tyrosyl alanine dipeptides substitués
ATE20804T1 (de) Chinoloncarbonsaeure enthaltende bakterizide mittel.
SE8302193L (sv) N-(1-substituerade-3-pyrrolidinyl)-bensamider och tiobensamider
GB1508772A (en) Biologically active compositions
JPS5651465A (en) Benzothiazine derivative
ES8304934A1 (es) "un procedimiento para la preparacion de nuevas fluoro-prostaciclinas".
DK174885A (da) Derivater af n-(3-phenylmethylthio-1-oxopropyl)-aminoeddikesyre i form af enantiomere eller blandinger, fremgangsmaade til fremstilling af forbindelserne og laegemiddel indeholdende disse
ES8604893A1 (es) Procedimiento para la obtencion de sulfonilguanidinas asime-tricas
TH1781A (th) อนุพันธุ์ของกรดอัลเคนไทโอคาร์บ๊อกซิลิค ที่มีกลุ่มแทนที่
ES8502428A1 (es) Procedimiento para preparar nuevas semicarbazidas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI HU JP KR

WWE Wipo information: entry into national phase

Ref document number: 872299

Country of ref document: FI

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI HU JP KR